BRAFV600E: Implications for carcinogenesis and molecular therapy

Molecular Cancer Therapeutics

Volumn 10, Issue 3, 2011, Pages 385-394

  Cantwell Dorris, Emma R ^a   O'Leary, John J ^a   Sheils, Orla M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL]ETHANOL; ALPHA INTERMEDIN; B RAF KINASE; B RAF KINASE INHIBITOR; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; IMATINIB; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PLX 4720; RAS PROTEIN; SELUMETINIB; SORAFENIB; TEMOZOLOMIDE; TRANSCRIPTION FACTOR E2F; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VEMURAFENIB; XL 281;

CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG TARGETING; GENE MUTATION; GENETIC VARIABILITY; GERM LINE; HUMAN; LEOPARD SYNDROME; MC1R GENE; MELANOGENESIS; MELANOMA; MOLECULAR BIOLOGY; MOLECULAR THERAPY; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; WILD TYPE; ANIMAL; CELL TRANSFORMATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; MUTATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 79955751512     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0799     Document Type: Review

References (74)

1. Garnett M, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-9. (Pubitemid 39361432)
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54. (Pubitemid 34716871)
3. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67. (Pubitemid 38410730)
4. Robinson M, Cobb M. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-6. (Pubitemid 27135985)
5. Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, Marais R. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 1999;18:2137-48.
6. Catling A, Schaeffer H, Reuter C, Reddy G, Weber M. A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function. Mol Cell Biol 1995;15:5214-25.
7. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004;91:355-8. Available from: http://www. sanger.ac.uk/cosmic. (Pubitemid 39037083)
8. Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 2009;23:529-45, ix.
9. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-62. (Pubitemid 40896444)
10. Gunson T, Hashim N, Sharpe G. Generalized lentiginosis, short stature, and multiple cutaneous nodules-quiz case. LEOPARD syndrome (LS) associated with multiple granular cell tumors (GCTs). Arch Dermatol 2010;146:337-42.
11. Urano Y, Asano T, Yoshimoto K, Iwahana H, Kubo Y, Kato S, et al. Frequent p53 accumulation in the chronically sun-exposed epidermis and clonal expansion of p53 mutant cells in the epidermis adjacent to basal cell carcinoma. J Invest Dermatol 1995;104:928-32.
12. Landi M, Bauer J, Pfeiffer R, Elder DE, Hulley B, Minghetti P, et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006;313:521-2. (Pubitemid 44148456)
13. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47. (Pubitemid 41653105)
14. Sturm R, Duffy D, Box N, Chen W, Smit DJ, Brown DL, et al. The role of melanocortin-1 receptor polymorphism in skin cancer risk pheno-types. Pigment Cell Res 2003;16:266-72. (Pubitemid 36597067)
15. Gerstenblith M, Goldstein A, Fargnoli M, Peris K, Landi M. Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat 2007;28:495-505. (Pubitemid 46668608)
16. Fargnoli M, Pike K, Pfeiffer R, Tsang S, Rozenblum E, Munroe DJ, et al. MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol 2008;128:2485-90.
17. Abdel-Malek Z, Knittel J, Kadekaro A, Swope V, Starner R. The melanocortin 1 receptor and the UV response of human melanocytes- a shift in paradigm. Photochem Photobiol 2008;84:501-8. (Pubitemid 351421403)
18. Hacker E, Hayward N. Germline MC1R variants and BRAF mutant melanoma. J Invest Dermatol 2008;128:2354-6.
19. Conner SR, Scott G, Aplin AE. Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells. J Biol Chem 2003;278:34548-54. (Pubitemid 37553304)
20. Bhatt KV, Spofford LS, Aram G, McMullen M, Pumiglia K, Aplin AE. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 2005;24:3459-71. (Pubitemid 40756247)
21. Buscà R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychène A, et al. Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J 2000;19:2900-10. (Pubitemid 30386762)
22. Boyle P, Langman J. ABC of colorectal cancer: epidemiology. BMJ 2000;321:805-8.
23. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70. (Pubitemid 26358996)
24. Fransén K, Klintenäs M, Osterström A, Dimberg J, Monstein H, Söderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004;25:527-33.
25. Rajagopalan H, Bardelli A, Lengauer C, Kinzler K, Vogelstein B, Velculescu V. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934. (Pubitemid 34976022)
26. Velho S, Moutinho C, Cirnes L, Albuquerque C, Hamelin R, Schmitt F, et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?BMC Cancer 2008;8:255.
27. Benhattar J, Losi L, Chaubert P, Givel J, Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993;104:1044-8. (Pubitemid 23090756)
28. Kikuchi H, Pino M, Zeng M, Shirasawa S, Chung D. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer. Cancer Res 2009;69:8499-506.
29. Weisenberger D, Siegmund K, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-93. (Pubitemid 43980599)
30. Deng G, Chen A, Hong J, Chae HS, Kim YS. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 1999;59:2029-3.
31. Park S, Rashid A, Lee J, Kim S, Hamilton S, Wu T. Frequent CpG island methylation in serrated adenomas of the colorectum. Am J Pathol 2003;162:815-22. (Pubitemid 36237490)
32. Yang S, Farraye F, Mack C, Posnik O, O'Brien M. BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol 2004;28:1452-9. (Pubitemid 39425511)
33. Dong S, Lee E, Jeon E, Park C, Kim K. Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Pathol 2005;18:170-8. (Pubitemid 40188623)
34. Tateyama H, Li W, Takahashi E, Miura Y, Sugiura H, Eimoto T. Apoptosis index and apoptosis-related antigen expression in serrated adenoma of the colorectum: the saw-toothed structure may be related to inhibition of apoptosis. Am J Surg Pathol 2002;26:249-56. (Pubitemid 34127506)
35. Erhardt P, Schremser EJ, Cooper GM. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 1999;19:5308-15. (Pubitemid 29339890)
36. Ikehara N, Semba S, Sakashita M, Aoyama N, Kasuga M, Yokozaki H. BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. Int J Cancer 2005;115:943-50. (Pubitemid 40791836)
37. Minoo P, Moyer M, Jass J. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J Pathol 2007;212:124-33. (Pubitemid 46852090)
38. Pruitt K, Ulkü A, Frantz K, Rojas RJ, Muniz-Medina VM, Rangnekar VM, et al. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem 2005;280:23363-70. (Pubitemid 40853250)
39. Hundahl S, Fleming I, Fremgen A, Menck H. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S. 1985-1995[see comments]. Cancer 1998;83:2638-48.
40. Santoro M, Melillo R, Carlomagno F, Fusco A, Vecchio G. Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 2002;963:116-21. (Pubitemid 34721703)
41. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003;22:4578-80. (Pubitemid 36920701)
42. Ciampi R, Nikiforov Y. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007;148:936-41.
43. Tang K, Lee C. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 2010;73:113-28.
44. Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res 2007;13:1341-9. (Pubitemid 46424076)
45. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007;92:2840-3. (Pubitemid 47037399)
46. Scipioni A, Ferretti E, Soda G, Tosi E, Bruno R, Costante G, et al. hNIS protein in thyroid: the iodine supply influences its expression and localization. Thyroid 2007;17:613-8. (Pubitemid 47311548)
47. Houben R, Becker J, Kappel A, Terheyden P, Bröcker EB, Goetz R, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004;3:6.
48. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-7. (Pubitemid 39551656)
49. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, , et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008;105:3041-6. (Pubitemid 351723664)
50. Flaherty K, Puzanov I, Kim K, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
51. Montagut C, Sharma S, Shioda T, McDermott U, Ulman M, Ulkus LE, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008;68:4853-61.
52. Poulikakos P, Zhang C, Bollag G, Shokat K, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30.
53. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-21.
54. Schwartz GK, Robertson S, Shen A, Wang E, Pace L, Dials H, et al. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. ASCO Meet Abstr 2009;27:3513.
55. Gray-Schopfer VC, Karasarides M, Hayward R, Marais R. Tumor necrosis factor-{alpha} blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res 2007;67:122-9. (Pubitemid 46142767)
56. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-[alpha] are resistant to skin carcinogenesis. Nat Med 1999;5:828-31. (Pubitemid 29318619)
57. Bergenwald C, Westermark G, Sander B. Variable expression of tumor necrosis factor alpha in human malignant melanoma localized by in situ hybridization for mRNA. Cancer Immunol Immunother 1997;44:335-40. (Pubitemid 27364614)
58. Solit D, Garraway L, Pratilas C, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62 (Pubitemid 43128863)
59. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5:810-6. (Pubitemid 29318616)
60. Fremin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 2010;3:8.
61. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47. (Pubitemid 39626217)
62. Wang J, Wilcoxen K, Nomoto K, Wu S. Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem 2007;7:1364-78. (Pubitemid 47471235)
63. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010;16:1924-37.
64. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139-46.
65. Board RE, Ellison G, Orr MCM, Kemsley KR, McWalter G, D , et al. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer 2009;101:1724-30.
66. Patel SP, Lazar AJ, Mahoney S, Vaughn C, Gonzalez N, Papadopoulos NE, et al. Clinical responses to AZD6244 (ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. J Clin Oncol 2010;Suppl:abstr8501.
67. Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009;8:709-23.
68. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, et al. PI3K Pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009;69:4286-93.
69. Wellbrock C, Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010;80:561-7.
70. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5
71. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596-9
72. Bedogni B, Welford S, Kwan A, Ranger-Moore J, Saboda K, PowellM. Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther 2006;5:3071-7.
73. Smalley K, Haass N, Brafford P, Lioni M, Flaherty K, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5:1136-44. (Pubitemid 43881305)
74. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-9.